David C Jackson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1079274/publications.pdf

Version: 2024-02-01

187	6,813	66343	88630
papers	citations	42 h-index	70 g-index

194	194	194	7700
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Reduced Antigenicity of the Hepatitis B Virus HBsAg Protein Arising as a Consequence of Sequence Changes in the Overlapping Polymerase Gene That Are Selected by Lamivudine Therapy. Virology, 2002, 293, 305-313.	2.4	480
2	T Cell Allorecognition via Molecular Mimicry. Immunity, 2009, 31, 897-908.	14.3	232
3	A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15440-15445.	7.1	226
4	Human CD8+ T cell cross-reactivity across influenza A, B and C viruses. Nature Immunology, 2019, 20, 613-625.	14.5	180
5	Highly Immunogenic and Totally Synthetic Lipopeptides as Self-Adjuvanting Immunocontraceptive Vaccines. Journal of Immunology, 2002, 169, 4905-4912.	0.8	172
6	New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nature Medicine, 2000, 6, 455-459.	30.7	147
7	Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5850-5855.	7.1	137
8	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nature Communications, 2021, 12, 2037.	12.8	125
9	TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease. Frontiers in Immunology, 2014, 5, 79.	4.8	121
10	A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease. Ophthalmology, 2017, 124, 43-52.	5.2	120
11	Changes in the antigenicity of the hemagglutinin moleculeof H3 influenza virus at acidic pH. Virology, 1983, 126, 587-599.	2.4	119
12	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Reports Medicine, 2021, 2, 100208.	6.5	115
13	Chicken Anemia Virus VP2 Is a Novel Dual Specificity Protein Phosphatase. Journal of Biological Chemistry, 2002, 277, 39566-39573.	3.4	102
14	Intranasal Administration of the TLR2 Agonist Pam2Cys Provides Rapid Protection against Influenza in Mice. Molecular Pharmaceutics, 2012, 9, 2710-2718.	4.6	96
15	Secondary Acylation of Klebsiella pneumoniae Lipopolysaccharide Contributes to Sensitivity to Antibacterial Peptides. Journal of Biological Chemistry, 2007, 282, 15569-15577.	3.4	95
16	Chitosan Microparticles and Nanoparticles as Biocompatible Delivery Vehicles for Peptide and Protein-Based Immunocontraceptive Vaccines. Molecular Pharmaceutics, 2012, 9, 81-90.	4.6	95
17	Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. Journal of Clinical Investigation, 2003, 111, 1365-1371.	8.2	89
18	Resistance to Celiac Disease in Humanized HLA-DR3-DQ2-Transgenic Mice Expressing Specific Anti-Gliadin CD4+ T Cells. Journal of Immunology, 2009, 182, 7440-7450.	0.8	85

#	Article	IF	Citations
19	Induction of Long-Term Memory CD8 + T Cells for Recall of Viral Clearing Responses against Influenza Virus. Journal of Virology, 2002, 76, 4212-4221.	3.4	77
20	Bioactivity in an Aggrecan 32â€mer Fragment Is Mediated via Tollâ€like Receptor 2. Arthritis and Rheumatology, 2015, 67, 1240-1249.	5.6	76
21	Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. EBioMedicine, 2021, 63, 103153.	6.1	76
22	Intranasal Vaccination with a Lipopeptide Containing a Conformationally Constrained Conserved Minimal Peptide, a Universal T Cell Epitope, and a Selfâ€Adjuvanting Lipid Protects Mice from Group A Streptococcus Challenge and Reduces Throat Colonization. Journal of Infectious Diseases, 2006, 194, 325-330.	4.0	72
23	Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. European Journal of Immunology, 2006, 36, 770-778.	2.9	71
24	Herpes Simplex Virus Antigens Directly Activate NK Cells via TLR2, Thus Facilitating Their Presentation to CD4 T Lymphocytes. Journal of Immunology, 2012, 188, 4158-4170.	0.8	61
25	Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design. Journal of Peptide Science, 2003, 9, 255-281.	1.4	59
26	A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. Journal of Hepatology, 2010, 53, 599-607.	3.7	57
27	Mice lacking the transcription factor subunit Rel can clear an influenza infection and have functional anti-viral cytotoxic T cells but do not develop an optimal antibody response. International Immunology, 1999, 11, 1431-1439.	4.0	54
28	Antigenic and immunogenic properties of totally synthetic peptide-based anti-fertility vaccines. International Immunology, 1999, 11, 1103-1110.	4.0	53
29	Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. International Immunology, 2006, 18, 1801-1813.	4.0	53
30	Antigenic competition in a multivalent foot rot vaccine. Vaccine, 1994, 12, 457-464.	3.8	52
31	Multi-epitope schistosome vaccine candidates tested for protective immunogenicity in mice. Vaccine, 2000, 19, 103-113.	3.8	50
32	Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens. Vaccine, 2000, 18, 1031-1039.	3.8	50
33	Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine, 2007, 25, 92-101.	3.8	50
34	A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine, 2008, 26, 4866-4875.	3.8	50
35	A synthetic peptide-based polyoxime vaccine construct of high purity and activity. Molecular Immunology, 1995, 32, 1031-1037.	2.2	49
36	Polymerization of Unprotected Synthetic Peptides:â€‰ A View toward Synthetic Peptide Vaccines. Journal of the American Chemical Society, 1997, 119, 1183-1188.	13.7	49

#	Article	IF	Citations
37	Differential effect of CD8+ and CD8â€“ dendritic cells in the stimulation of secondary CD4+ T cells. International Immunology, 2001, 13, 465-473.	4.0	49
38	Affinity Thresholds for Naive CD8+ CTL Activation by Peptides and Engineered Influenza A Viruses. Journal of Immunology, 2011, 187, 5733-5744.	0.8	49
39	Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus. Immunology, 2001, 104, 58-66.	4.4	48
40	Antiâ€drug vaccines to treat substance abuse. Immunology and Cell Biology, 2009, 87, 309-314.	2.3	48
41	Defence against the immune barrage: Helminth survival strategies. Immunology and Cell Biology, 1996, 74, 564-574.	2.3	47
42	Free radical induced polymerization of synthetic peptides into polymeric immunogens. Vaccine, 1997, 15, 1697-1705.	3.8	45
43	Hepatitis C VLPs Delivered to Dendritic Cells by a TLR2 Targeting Lipopeptide Results in Enhanced Antibody and Cell-Mediated Responses. PLoS ONE, 2012, 7, e47492.	2.5	44
44	Precursor Frequency and Competition Dictate the HLA-A2â€“Restricted CD8+ T Cell Responses to Influenza A Infection and Vaccination in HLA-A2.1 Transgenic Mice. Journal of Immunology, 2011, 187, 1895-1902.	0.8	43
45	Antibodies elicited by influenza virus hemagglutinin fail to bind to synthetic peptides representing putative antigenic sites. Molecular Immunology, 1985, 22, 145-154.	2.2	42
46	Antigenic determinants of influenza virus hemagglutinin XII. The epitopes of a synthetic peptide representing the C-terminus of HA1. Virology, 1986, 155, 625-632.	2.4	42
47	Immunological parameters associated with antigenic competition in a multivalent footrot vaccine. Vaccine, 1995, 13, 1649-1657.	3.8	42
48	Lipid-based Self-Adjuvanting Vaccines. Current Drug Delivery, 2005, 2, 383-393.	1.6	41
49	The Context of Epitope Presentation Can Influence Functional Quality of Recalled Influenza A Virus-Specific Memory CD8+ T Cells. Journal of Immunology, 2007, 179, 2187-2194.	0.8	41
50	Soluble Proteins Induce Strong CD8+ T Cell and Antibody Responses through Electrostatic Association with Simple Cationic or Anionic Lipopeptides That Target TLR2. Journal of Immunology, 2011, 187, 1692-1701.	0.8	41
51	Single step enrichment of blood dendritic cells by positive immunoselection. Journal of Immunological Methods, 2003, 274, 47-61.	1.4	40
52	Promiscuous Peptide of 16 kDa Antigen Linked to Pam2Cys Protects Against Mycobacterium tuberculosis by Evoking Enduring Memory T-Cell Response. Journal of Infectious Diseases, 2011, 204, 1328-1338.	4.0	38
53	Assembly of synthetic peptide vaccines by chemoselective ligation of epitopes: influence of different chemical linkages and epitope orientations on biological activity. Vaccine, 2001, 19, 3843-3852.	3.8	37
54	Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. Amino Acids, 2010, 39, 471-480.	2.7	37

#	Article	IF	Citations
55	An Insect Antibacterial Peptide-Based Drug Delivery System. Molecular Pharmaceutics, 2004, 1, 220-232.	4.6	35
56	Antigenic determinants of influenza virus hemagglutinin XI. Conformational chantes detected by monoclonal antibodies. Virology, 1985, 145, 72-83.	2.4	34
57	Synthesis and conformational analysis of N-glycopeptides that contain extended sugar chains. Tetrahedron, 1994, 50, 2373-2390.	1.9	34
58	The assembly and immunological properties of non-linear synthetic immunogens containing T-cell and B-cell determinants. Vaccine, 1996, 14, 553-560.	3.8	34
59	The design and proof of concept for a CD8⁺ T cellâ€based vaccine inducing crossâ€subtype protection against influenza A virus. Immunology and Cell Biology, 2013, 91, 96-104.	2.3	34
60	Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity. MBio, 2015, 6, e01024-15.	4.1	34
61	Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients. Nature Communications, 2021, 12, 2691.	12.8	34
62	Low-molecular-weight Ia antigens in normal mouse serum. Immunogenetics, 1976, 3, 455-463.	2.4	33
63	Analysis of the interaction between a synthetic peptide of influenza virus hemagglutinin and monoclonal antibodies using an optical biosensor. Molecular Immunology, 1996, 33, 659-670.	2.2	33
64	Plasmodium falciparum Merozoite Surface Protein 6 Is a Dimorphic Antigen. Infection and Immunity, 2004, 72, 2321-2328.	2.2	33
65	Synthesis of a New Template with a Built-in Adjuvant and Its Use in Constructing Peptide Vaccine Candidates Through Polyoxime Chemistry. Journal of Peptide Science, 1996, 2, 66-72.	1.4	32
66	The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. Molecular Immunology, 2007, 44, 3724-3731.	2.2	31
67	A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunology and Cell Biology, 2010, 88, 605-611.	2.3	31
68	Modulating Contact Lens Discomfort With Anti-Inflammatory Approaches: A Randomized Controlled Trial. , 2018, 59, 3755.		31
69	Antigenic activity of a synthetic peptide comprising the â€œloopâ€•region of influenza virus hemagglutinin. Virology, 1982, 120, 273-276.	2.4	30
70	Glycosylation of a Synthetic Peptide Representing a T-Cell Determinant of Influenza Virus Hemagglutinin Results in Loss of Recognition by CD4+ T-Cell Clones. Virology, 1994, 199, 422-430.	2.4	30
71	Recent Advances with TLR2-Targeting Lipopeptide-Based Vaccines. Current Protein and Peptide Science, 2007, 8, 412-417.	1.4	30
72	A partially structured region of a largely unstructured protein, Plasmodium falciparum merozoite surface protein 2 (MSP2), forms amyloidâ€like fibrils. Journal of Peptide Science, 2007, 13, 839-848.	1.4	30

#	Article	IF	Citations
73	Spirituality, spiritual need, and spiritual care in aged care: What the literature says. Journal of Religion, Spirituality and Aging, 2016, 28, 281-295.	0.7	30
74	A 320-Kilobase Artificial Chromosome Encoding the Human HLA DR3-DQ2 MHC Haplotype Confers HLA Restriction in Transgenic Mice. Journal of Immunology, 2002, 168, 3050-3056.	0.8	29
75	PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8+ T cell responses. Biomaterials, 2017, 137, 61-72.	11.4	29
76	Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. International Immunology, 1999, 11, 569-576.	4.0	28
77	Definition of T cell epitopes within the 19â€ƒkDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP119) and their role in immunity to malaria. Parasite Immunology, 2002, 20, 263-278.	1.5	28
78	Totally synthetic peptide-based immunocontraceptive vaccines show activity in dogs of different breeds. Vaccine, 2007, 25, 7111-7119.	3.8	28
79	The use of a TLR2 agonistâ€based adjuvant for enhancing effector and memory CD8 Tâ€cell responses. Immunology and Cell Biology, 2014, 92, 377-383.	2.3	28
80	The Influenza Virusâ€“Specific CTL Immunodominance Hierarchy in Mice Is Determined by the Relative Frequency of High-Avidity T Cells. Journal of Immunology, 2014, 192, 4061-4068.	0.8	28
81	Tear film inflammatory cytokine upregulation in contact lens discomfort. Ocular Surface, 2019, 17, 89-97.	4.4	28
82	Robust correlations across six SARSâ€CoVâ€2 serology assays detecting distinct antibody features. Clinical and Translational Immunology, 2021, 10, e1258.	3.8	28
83	Chemical and antigenic characterization of the carbohydrate side chains of an Asian (N2) influenza virus neuraminidases. Virology, 1983, 126, 370-375.	2.4	27
84	Conserved Determinants for CD4+ T Cells within the Light Chain of the H3 Hemagglutinin Molecule of Influenza Virus. Virology, 1994, 198, 613-623.	2.4	27
85	The geometry of synthetic peptide-based immunogens affects the efficiency of T cell stimulation by professional antigen-presenting cells. International Immunology, 2000, 12, 527-535.	4.0	27
86	Effects on Rotavirus Cell Binding and Infection of Monomeric and Polymeric Peptides Containing Î±2Î²1 and Î±xÎ²2 Integrin Ligand Sequences. Journal of Virology, 2004, 78, 11786-11797.	3.4	27
87	Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. Journal of Clinical Virology, 2004, 30, 283-290.	3.1	27
88	Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunology and Cell Biology, 2003, 81, 67-72.	2.3	26
89	A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus. Hepatology, 2007, 45, 911-920.	7.3	26
90	A Modular Approach to Assembly of Totally Synthetic Self-adjuvanting Lipopeptide-based Vaccines Allows Conformational Epitope Building. Journal of Biological Chemistry, 2011, 286, 12944-12951.	3.4	26

#	Article	IF	Citations
91	Antigen-Driven Patterns of TCR Bias Are Shared across Diverse Outcomes of Human Hepatitis C Virus Infection. Journal of Immunology, 2011, 186, 901-912.	0.8	26
92	Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine, 1998, 16, 2058-2068.	3.8	25
93	Synthesis of Toll-Like Receptor-2 Targeting Lipopeptides as Self-Adjuvanting Vaccines. Methods in Molecular Biology, 2008, 494, 247-261.	0.9	25
94	Modulation of CD4+ T-Cell Recognition of Influenza Hemagglutinin by Carbohydrate Side Chains Located Outside a T-Cell Determinant. Virology, 1993, 192, 282-289.	2.4	24
95	Preparation and properties of totally synthetic immunogens. Vaccine, 1999, 18, 355-361.	3.8	24
96	A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli. Vaccine, 2012, 30, 4800-4806.	3.8	24
97	Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses. PLoS ONE, 2015, 10, e0129768.	2.5	24
98	Analysis of Immunological Nonresponsiveness to the 19-Kilodalton Fragment of Merozoite Surface Protein 1 of Plasmodium yoelii : Rescue by Chemical Conjugation to Diphtheria Toxoid (DT) and Enhancement of Immunogenicity by Prior DT Vaccination. Infection and Immunity, 2003, 71, 5700-5713.	2.2	23
99	Lipidated promiscuous peptides vaccine for tuberculosis-endemic regions. Trends in Molecular Medicine, 2012, 18, 607-614.	6.7	22
100	Control of size dispersity of chitosan biopolymer microparticles and nanoparticles to influence vaccine trafficking and cell uptake. Journal of Biomedical Materials Research - Part A, 2012, 100A, 1859-1867.	4.0	22
101	Simultaneous binding of two monoclonal antibodies to epitopes separated in sequence by only three amino acid residues. Molecular Immunology, 1988, 25, 465-471.	2.2	21
102	Mutation of chicken anemia virus VP2 differentially affects serine/threonine and tyrosine protein phosphatase activities. Journal of General Virology, 2005, 86, 623-630.	2.9	21
103	T cell epitopes of the La/SSB autoantigen in humanized transgenic mice expressing the hLa class II haplotype DRB1*0301/DQB1*0201. Arthritis and Rheumatism, 2007, 56, 3387-3398.	6.7	21
104	Salivary Blockade Protects the Lower Respiratory Tract of Mice from Lethal Influenza Virus Infection. Journal of Virology, 2017, 91, .	3.4	21
105	Neoepitope Antibodies Against MMP-Cleaved and Aggrecanase-Cleaved Aggrecan. Methods in Molecular Biology, 2010, 622, 305-340.	0.9	21
106	Antigenic determinants of influenza virus hemagglutininâ€”IX. The carbohydrate side chains from an Asian strain. Molecular Immunology, 1982, 19, 329-338.	2.2	20
107	Neutralising Antibody, CTL and Dendritic Cell Responses to Hepatitis C Virus: A Preventative Vaccine Strategy. Current Drug Targets, 2004, 5, 41-56.	2.1	20
108	Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses. Vaccine, 2008, 26, 2570-2579.	3.8	20

#	Article	IF	Citations
109	CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph. Nature Communications, 2021, 12, 2931.	12.8	20
110	Lipidation of intact proteins produces highly immunogenic vaccine candidates. Molecular Immunology, 2011, 48, 490-496.	2.2	19
111	A single dose biodegradable vaccine depot that induces persistently high levels of antibody over a year. Biomaterials, 2015, 53, 50-57.	11.4	19
112	A novel therapeutic strategy of lipidated promiscuous peptide against Mycobacterium tuberculosis by eliciting Th1 and Th17 immunity of host. Scientific Reports, 2016, 6, 23917.	3.3	19
113	Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. Vaccine, 2005, 23, 4427-4435.	3.8	18
114	Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response. Clinical Immunology, 2008, 128, 329-339.	3.2	18
115	Preemptive priming readily overcomes structure-based mechanisms of virus escape. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5570-5575.	7.1	18
116	Reducing the impact of influenzaâ€assˆociated secondary pneumococcal infections. Immunology and Cell Biology, 2016, 94, 101-108.	2.3	18
117	Antigenic determinants of influenza virus hemagglutinin VII. The carbohydrate side chains of A/Memphis/102/72 hemagglutinin heavy chain which cross-react with host antigen. Virology, 1981, 108, 71-79.	2.4	17
118	Polyfunctional CD8+ T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope. Antiviral Research, 2012, 94, 168-178.	4.1	17
119	A lipidated form of the extracellular domain of influenza M2 protein as a self-adjuvanting vaccine candidate. Vaccine, 2015, 33, 3526-3532.	3.8	17
120	Establishment of memory CD8+ T cells with live attenuated influenza virus across different vaccination doses. Journal of General Virology, 2016, 97, 3205-3214.	2.9	17
121	Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and Tâ€helper epitopes. Immunology and Cell Biology, 2007, 85, 169-173.	2.3	16
122	TLR2-mediated innate immune priming boosts lung anti-viral immunity. European Respiratory Journal, 2021, 58, 2001584.	6.7	16
123	Identification of key residues involved in fibril formation by the conserved N-terminal region of Plasmodium falciparum merozoite surface protein 2 (MSP2). Biochimie, 2010, 92, 1287-1295.	2.6	15
124	TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs. JCI Insight, 2021, 6, .	5.0	15
125	Selecting and Using the Appropriate Influenza Vaccine for Each Individual. Viruses, 2021, 13, 971.	3.3	15
126	Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2022, 23, 835.	4.1	15

#	Article	IF	Citations
127	Exploiting Information Inherent in Binding Sites of Virus-Specific Antibodies: Design of An HCV Vaccine Candidate Cross-Reactive with Multiple Genotypes. Antiviral Therapy, 2006, 11, 1005-1014.	1.0	15
128	Extension of a minimal T cell Determinant allows relaxation of the requirement for particular residues within the determinant. International Immunology, 1991, 3, 1307-1313.	4.0	14
129	Bypassing luminal barriers, delivery to a gut addressin by parenteral targeting elicits local IgA responses. International Immunology, 2004, 16, 1613-1622.	4.0	14
130	A lipidated peptide of Mycobacterium tuberculosis resuscitates the protective efficacy of BCG vaccine by evoking memory T cell immunity. Journal of Translational Medicine, 2017, 15, 201.	4.4	14
131	Western blot analysis of antibody responses to influenza virion proteins. Immunology and Cell Biology, 1992, 70, 181-191.	2.3	13
132	A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis. Journal of Translational Medicine, 2018, 16, 279.	4.4	13
133	Lipopeptide vaccines illustrate the potential role of subtypeâ€crossreactive T cells in the control of highly virulent influenza. Influenza and Other Respiratory Viruses, 2009, 3, 177-182.	3.4	12
134	Opinion: Making Inactivated and Subunit-Based Vaccines Work. Viral Immunology, 2018, 31, 150-158.	1.3	12
135	The stoichiometry of binding between monoclonal antibody molecules and the hemagglutinin of influenza virus. Virology, 1990, 179, 768-776.	2.4	11
136	Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model. Infection and Immunity, 2020, 88, .	2.2	11
137	Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes. Antiviral Therapy, 2006, 11, 1005-14.	1.0	11
138	Detection and isolation of an Ia glycoprotein antigen from mouse serum. Immunogenetics, 1977, 4, 267-279.	2.4	10
139	Conformational changes in influenza virus haemagglutinin and its monomer detected by monoclonal antibodies. Vaccine, 1985, 3, 175-181.	3.8	10
140	Manipulation of the helper T cell response to influence antigenic competition occurring with a multivalent vaccine. Immunology and Cell Biology, 1996, 74, 81-89.	2.3	10
141	T CD8 response in diverse outcomes of recurrent exposure to hepatitis C virus. Immunology and Cell Biology, 2009, 87, 464-472.	2.3	10
142	Chitosan-based particles as biocompatible delivery vehicles for peptide and protein-based vaccines. Procedia in Vaccinology, 2012, 6, 74-79.	0.4	10
143	Prior Population Immunity Reduces the Expected Impact of CTL-Inducing Vaccines for Pandemic Influenza Control. PLoS ONE, 2015, 10, e0120138.	2.5	10
144	Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists. Viral Immunology, 2018, 31, 338-343.	1.3	10

#	Article	IF	Citations
145	High antibody titres induced by protein subunit vaccines usingMycobacterium ulceransantigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice. PeerJ, 2020, 8, e9659.	2.0	10
146	Immune responses in hepatitis C virus infection: The role of dendritic cells. Immunology and Cell Biology, 2003, 81, 63-66.	2.3	9
147	Establishment of functional influenza virus-specific CD8+ T cell memory pools after intramuscular immunization. Vaccine, 2015, 33, 5148-5154.	3.8	9
148	Challenges and solutions for a rational vaccine design for TB-endemic regions. Critical Reviews in Microbiology, 2015, 41, 389-398.	6.1	9
149	Competition within the virusâ€specific CD4 Tâ€cell pool limits the T follicular helper response after influenza infection. Immunology and Cell Biology, 2016, 94, 729-740.	2.3	9
150	Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLRâ€2 agonist Pam 2 Cys. Immunology and Cell Biology, 2016, 94, 169-176.	2.3	9
151	Structureâ€“function relationships of proteinâ€“lipopeptide complexes and influence on immunogenicity. Amino Acids, 2017, 49, 1691-1704.	2.7	9
152	The endogenous inflammatory reflex inhibits the inflammatory response to different immune challenges in mice. Brain, Behavior, and Immunity, 2021, 97, 371-375.	4.1	9
153	In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model. American Journal of Tropical Medicine and Hygiene, 2019, 101, 1312-1321.	1.4	9
154	Quantitative analysis of the interaction between lysozyme and monoclonal antibody D1.3. Molecular Immunology, 1993, 30, 47-54.	2.2	8
155	Dendritic Cell Immunotherapy of Hepatitis C Virus Infection: Toxicology of Lipopeptide-Loaded Dendritic Cells. International Journal of Peptide Research and Therapeutics, 2005, 11, 223-235.	1.9	8
156	Dendritic cell acquisition of epitope cargo mediated by simple cationic peptide structures. Peptides, 2008, 29, 881-890.	2.4	8
157	Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2Cys. Frontiers in Immunology, 2015, 6, 290.	4.8	8
158	Extrinsically derived TNF is primarily responsible for limiting antiviral CD8+ T cell response magnitude. PLoS ONE, 2017, 12, e0184732.	2.5	8
159	The Toll-Like Receptor 2 agonist PEG-Pam2Cys as an immunochemoprophylactic and immunochemotherapeutic against the liver and transmission stages of malaria parasites. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 451-458.	3.4	8
160	Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells. Vaccine, 2021, 39, 3940-3951.	3.8	8
161	Induction of Multi-Functional T Cells in a Phase I Clinical Trial of Dendritic Cell Immunotherapy in Hepatitis C Virus Infected Individuals. PLoS ONE, 2012, 7, e39368.	2.5	8
162	Identification of dominant epitopes of synthetic immunocontraceptive vaccines that induce antibodies in dogs. Vaccine, 2005, 23, 4589-4597.	3.8	7

#	Article	IF	Citations
163	Impaired dendritic cell maturation in response to pandemic H1N109 influenza virus. Journal of Clinical Virology, 2013, 56, 310-315.	3.1	7
164	Different Arms of the Adaptive Immune System Induced by a Combination Vaccine Work in Concert to Provide Enhanced Clearance of Influenza. PLoS ONE, 2014, 9, e115356.	2.5	7
165	Synthetic peptide antigens induce antibodies to Taenia ovis oncospheres. Vaccine, 1999, 17, 1506-1515.	3.8	6
166	The antigenic and immunogenic properties of synthetic peptide immunocontraceptive vaccine candidates based on gamete antigens. Vaccine, 1999, 18, 416-425.	3.8	6
167	Identification of antigenically active tryptic fragments of apical membrane antigen-1 (AMA1) of Plasmodium chabaudi malaria: strategies for assembly of immunologically active peptides. Vaccine, 2002, 20, 3477-3484.	3.8	6
168	Immune profiling of influenzaâ€specific Bâ€and Tâ€cell responses in macaques using flow cytometryâ€based assays. Immunology and Cell Biology, 2021, 99, 97-106.	2.3	6
169	A study of the advantages and limitations of immunoblotting procedures for the detection of antibodies against influenza virus. Electrophoresis, 1993, 14, 926-936.	2.4	5
170	Memory cytolytic T-lymphocytes: induction, regulation and implications for vaccine design. Expert Review of Vaccines, 2005, 4, 711-723.	4.4	5
171	Probing the idiotype/anti-idiotype antibody interaction with a set of synthetic peptide homologues. Immunology Letters, 1991, 28, 213-218.	2.5	4
172	Synthetic peptides induce antibodies in sheep againstTaenia ovis. International Journal of Peptide Research and Therapeutics, 1999, 6, 303-312.	0.1	4
173	Considerations for the rapid deployment of vaccines against H7N9 influenza. Expert Review of Vaccines, 2014, 13, 1327-1337.	4.4	4
174	Geometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific Immune Response. Molecular Pharmaceutics, 2019, 16, 2037-2047.	4.6	4
175	Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population. Vaccine, 2020, 38, 597-607.	3.8	4
176	ANTIGENIC CARBOHYDRATE DETERMINANTS ON INFLUENZA HEMAGGLUTININ. , 1981, , 233-252.		4
177	Totally synthetic peptide-based vaccines that target dendritic cells and induce potent antibody or CTL responses. International Congress Series, 2006, 1289, 311-315.	0.2	3
178	Role of CD8+T-cell immunity in influenza infection: potential use in future vaccine development. Expert Review of Respiratory Medicine, 2009, 3, 523-537.	2.5	3
179	Simple Branched Arginine-Based Structures can Enhance the Cellular Uptake of Peptide Cargos. International Journal of Peptide Research and Therapeutics, 2007, 13, 431-437.	1.9	1
180	Chemical Synthesis of Monomeric, Dimeric and Tetrameric Forms of the Ectodomain of Influenza Matrix 2 Protein. European Journal of Organic Chemistry, 2016, 2016, 1054-1059.	2.4	1

#	Article	IF	Citations
181	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. Expert Review of Vaccines, 2022, 21, 1055-1070.	4.4	1
182	peptide probes. Molecular Immunology, 1994, 31, 289-299.	2.2	0
183	Synthetic peptides induce antibodies in sheep against Taenia ovis. International Journal of Peptide Research and Therapeutics, 1999, 6, 303-312.	0.1	0
184	Intranasal vaccination with a lipopeptide containing a minimal, conserved M-protein derived peptide and a self-adjuvanting lipid induces both systemic and mucosal immune responses in mice. International Congress Series, 2006, 1289, 316-319.	0.2	0
185	Electrostatic-mediated enhancement of protein antigen immunogenicity using charged TLR2-targeting lipopeptides. Procedia in Vaccinology, 2012, 6, 80-84.	0.4	0
186	Immunochemical and Crystallographic Studies on the Interaction between Antibody and a Synthetic Peptide of Influenza Hemagglutinin. , 1990, , 75-85.		0
187	Lipidated promiscuous peptide augments the expression of MHC-II molecules on dendritic cells and activates T cells. Indian Journal of Medical Research, 2013, 138, 744-8.	1.0	0